Filing Details

Accession Number:
0001209191-17-015990
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-03-01 17:12:49
Reporting Period:
2017-02-27
Filing Date:
2017-03-01
Accepted Time:
2017-03-01 17:12:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
907654 Arca Biopharma Inc. ABIO In Vitro & In Vivo Diagnostic Substances (2835) 363855489
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1628992 L. Brian Selby 11080 Circlepoint Road
Suite 140
Westminster CO 80020
Vp, Finance No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-02-27 161 $2.56 2,389 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2017-02-27 24,100 $0.00 24,100 $2.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
24,100 2027-02-26 No 4 A Direct
Footnotes
  1. Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan").
  2. Includes (i) remaining 161 previously reported shares issued as RSUs under the Plan that vest on 2/27/18, and (ii) 2,228 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan.
  3. Grant to the Reporting Person of a stock option under the Plan, 50% vesting upon achievement of certain pre-specified corporate milestone related to the outcome of the interim data analysis by that trial's Data and Safety Monitoring Board, and if the milestone is achieved, the remainder of the grant will vest on March 31, 2018, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. If the corporate milestone is not achieved, the Option will be cancelled.In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.